CN109563154B - 抗帕多瓦因子ix抗体 - Google Patents

抗帕多瓦因子ix抗体 Download PDF

Info

Publication number
CN109563154B
CN109563154B CN201780044200.9A CN201780044200A CN109563154B CN 109563154 B CN109563154 B CN 109563154B CN 201780044200 A CN201780044200 A CN 201780044200A CN 109563154 B CN109563154 B CN 109563154B
Authority
CN
China
Prior art keywords
antibody
binding fragment
antigen
factor
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780044200.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN109563154A (zh
Inventor
D·沃克
R·帕其林格
H·罗特施泰纳
A·韦伯
A·艾格美亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59067875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN109563154(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CN109563154A publication Critical patent/CN109563154A/zh
Application granted granted Critical
Publication of CN109563154B publication Critical patent/CN109563154B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/9645—Factor IX (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN201780044200.9A 2016-05-16 2017-05-16 抗帕多瓦因子ix抗体 Active CN109563154B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662337118P 2016-05-16 2016-05-16
US62/337,118 2016-05-16
US201662340834P 2016-05-24 2016-05-24
US62/340,834 2016-05-24
PCT/US2017/032808 WO2017200981A1 (en) 2016-05-16 2017-05-16 Anti-factor ix padua antibodies

Publications (2)

Publication Number Publication Date
CN109563154A CN109563154A (zh) 2019-04-02
CN109563154B true CN109563154B (zh) 2024-12-13

Family

ID=59067875

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780044200.9A Active CN109563154B (zh) 2016-05-16 2017-05-16 抗帕多瓦因子ix抗体

Country Status (12)

Country Link
US (2) US11098132B2 (enExample)
EP (1) EP3458477B1 (enExample)
JP (3) JP7084878B2 (enExample)
KR (2) KR102625416B1 (enExample)
CN (1) CN109563154B (enExample)
AU (1) AU2017268198C1 (enExample)
BR (1) BR112018073660A2 (enExample)
CA (1) CA3024485A1 (enExample)
IL (1) IL262813B2 (enExample)
RU (2) RU2022108606A (enExample)
SG (1) SG11201809642TA (enExample)
WO (1) WO2017200981A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
CN110343181B (zh) * 2018-04-08 2022-04-08 苏州康宁杰瑞生物科技有限公司 针对凝血因子ix(fix)的单域抗体
LT3723858T (lt) 2018-12-21 2022-02-10 Kymab Limited Fixaxfx bispecifiniai antikūnai, turintys bendrą lenvąją grandinę
GB202009928D0 (en) * 2020-06-29 2020-08-12 Freeline Therapeutics Ltd Method
KR102749341B1 (ko) * 2022-07-08 2025-01-06 노보 노르디스크 에이/에스 FVIII(a)를 치환할 수 있는 매우 강력한 ISVD 화합물
CN116217674B (zh) * 2023-02-07 2024-08-02 湖南九典制药股份有限公司 一种抗菌/抗炎多肽及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201427685A (zh) * 2012-09-25 2014-07-16 Biogen Idec Inc Ｆｉｘ多肽的應用
EP2881463A1 (en) * 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5780279A (en) 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5855885A (en) 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
EP0826696B1 (de) 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
JP4669984B2 (ja) 2001-01-19 2011-04-13 ベジェニクス リミテッド 腫瘍画像化のターゲットとしてのＦ１ｔ４（ＶＥＧＦＲ−３）および抗腫瘍療法
US20040096983A1 (en) * 2002-11-14 2004-05-20 Jacobs Merrit N. Wash process for a sample being analyzed
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7297336B2 (en) * 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
WO2005087812A1 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
EP1876236B9 (en) * 2005-04-08 2015-02-25 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
US8234784B2 (en) 2008-02-13 2012-08-07 Younger Steven W Valve piston repositioning apparatus and method
DK2911687T3 (da) 2012-10-26 2019-05-13 Univ Brussel Vrije Vektor til levermålrettet genterapi af hæmofili og fremgangsmåder og anvendelse deraf
WO2016004113A1 (en) * 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201427685A (zh) * 2012-09-25 2014-07-16 Biogen Idec Inc Ｆｉｘ多肽的應用
EP2881463A1 (en) * 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders

Also Published As

Publication number Publication date
EP3458477B1 (en) 2025-07-09
CA3024485A1 (en) 2017-11-23
KR102625416B1 (ko) 2024-01-15
NZ747752A (en) 2025-05-30
AU2017268198B2 (en) 2020-09-03
WO2017200981A8 (en) 2018-02-01
RU2018138782A3 (enExample) 2020-07-14
US11999798B2 (en) 2024-06-04
CN109563154A (zh) 2019-04-02
SG11201809642TA (en) 2018-11-29
EP3458477A1 (en) 2019-03-27
JP7671887B2 (ja) 2025-05-02
KR102481704B1 (ko) 2022-12-27
AU2017268198C1 (en) 2020-11-26
IL262813B1 (en) 2025-08-01
JP7084878B2 (ja) 2022-06-15
US11098132B2 (en) 2021-08-24
WO2017200981A1 (en) 2017-11-23
KR20230006026A (ko) 2023-01-10
JP2024056941A (ja) 2024-04-23
RU2022108606A (ru) 2022-04-11
IL262813B2 (en) 2025-12-01
KR20190006548A (ko) 2019-01-18
RU2018138782A (ru) 2020-06-17
RU2770006C2 (ru) 2022-04-14
JP2022133276A (ja) 2022-09-13
AU2017268198A1 (en) 2018-11-22
US20220056150A1 (en) 2022-02-24
US20190194351A1 (en) 2019-06-27
BR112018073660A2 (pt) 2019-02-19
JP2019527033A (ja) 2019-09-26
IL262813A (en) 2018-12-31

Similar Documents

Publication Publication Date Title
JP7671887B2 (ja) 抗第ＩＸ因子Ｐａｄｕａ抗体
WO2019184912A1 (zh) 抗cd47抗体及其用途
WO2016073906A2 (en) Transforming growth factor-related immunoassays
CN110914300A (zh) 使用ps靶向抗体与免疫肿瘤学药剂治疗癌症的方法
CN103459595B (zh) 针对人前列腺素e2受体ep4的抗体
JP6851322B2 (ja) 神経疾患を治療する方法
RS58141B1 (sr) Anti-cxcr3 antitela
CN115925935A (zh) 抗人gpvi抗体及其用途
JP5765814B2 (ja) インテグリンα８β１特異的モノクローナル抗体
JP2016000713A (ja) 線維芽細胞増殖因子４に対するハイブリドーマクローンおよびモノクローナル抗体
JPWO2011049082A6 (ja) インテグリンα８β１特異的モノクローナル抗体
US11802151B2 (en) Brain-specific angiogenesis inhibitor 1 (BAI1) antibodies and uses thereof
JP2018513141A (ja) ヒトカドヘリン−１７、ヒトカドヘリン−５、ヒトカドヘリン−６およびヒトカドヘリン−２０のｒｇｄモチーフに特異的に結合する薬剤
TWI782000B (zh) 抗ｇｐｒ２０抗體、其製造方法及其應用
JP2024542488A (ja) 終末糖化産物受容体（ｒａｇｅ）に対する抗体及びその使用
JP2024508222A (ja) 抗Ｍｃｌ１抗体を投与することによる癌を監視するための材料及び方法
JP2020528932A (ja) Ｃｄ９ｐ−１標的化抗体およびその使用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210708

Address after: Osaka

Applicant after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Illinois, USA

Applicant before: Bayco Celta

Applicant before: Baixelta LLC

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment